Update shared on 14 Dec 2025
Fair value Decreased 1.21%Narrative Update
Analysts have modestly trimmed their fair value estimate for Mankind Pharma to ₹3,260 from ₹3,300, reflecting slightly lower expected revenue growth and valuation multiples, partly offset by an improved profit margin outlook.
What's in the News
- Board meeting scheduled for November 6, 2025, to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments)
Valuation Changes
- Fair Value Estimate reduced slightly to ₹3,260 from ₹3,300, reflecting a modest downward revision in intrinsic value.
- Discount Rate inched up marginally to 12.76 percent from 12.73 percent, implying a slightly higher required return.
- Revenue Growth trimmed moderately to 15.79 percent from 16.63 percent, indicating a more conservative topline outlook.
- Net Profit Margin improved slightly to 19.75 percent from 19.34 percent, pointing to better expected profitability.
- Future P/E decreased meaningfully to 50.08x from 53.81x, suggesting a modest derating in forward valuation multiples.
Have other thoughts on Mankind Pharma?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.